JP2016531151A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531151A5
JP2016531151A5 JP2016542319A JP2016542319A JP2016531151A5 JP 2016531151 A5 JP2016531151 A5 JP 2016531151A5 JP 2016542319 A JP2016542319 A JP 2016542319A JP 2016542319 A JP2016542319 A JP 2016542319A JP 2016531151 A5 JP2016531151 A5 JP 2016531151A5
Authority
JP
Japan
Prior art keywords
weight
coated tablet
tablet according
amount
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016542319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531151A (ja
Filing date
Publication date
Priority claimed from EP13184229.6A external-priority patent/EP2848246A1/en
Application filed filed Critical
Priority claimed from PCT/EP2014/069453 external-priority patent/WO2015036512A1/en
Publication of JP2016531151A publication Critical patent/JP2016531151A/ja
Publication of JP2016531151A5 publication Critical patent/JP2016531151A5/ja
Pending legal-status Critical Current

Links

JP2016542319A 2013-09-13 2014-09-11 レファメチニブを含有する医薬組成物 Pending JP2016531151A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13184229.6A EP2848246A1 (en) 2013-09-13 2013-09-13 Pharmaceutical compositions containing refametinib
EP13184229.6 2013-09-13
EP13184539 2013-09-16
EP13184539.8 2013-09-16
PCT/EP2014/069453 WO2015036512A1 (en) 2013-09-13 2014-09-11 Pharmaceutical compositions containing refametinib

Publications (2)

Publication Number Publication Date
JP2016531151A JP2016531151A (ja) 2016-10-06
JP2016531151A5 true JP2016531151A5 (enExample) 2017-10-19

Family

ID=51541077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016542319A Pending JP2016531151A (ja) 2013-09-13 2014-09-11 レファメチニブを含有する医薬組成物

Country Status (13)

Country Link
US (1) US20160220494A1 (enExample)
EP (1) EP3043778B1 (enExample)
JP (1) JP2016531151A (enExample)
CN (1) CN105658209A (enExample)
CA (1) CA2923990A1 (enExample)
DK (1) DK3043778T3 (enExample)
ES (1) ES2648267T3 (enExample)
HU (1) HUE035877T2 (enExample)
NO (1) NO3043778T3 (enExample)
PL (1) PL3043778T3 (enExample)
TW (1) TW201542245A (enExample)
UY (1) UY35734A (enExample)
WO (1) WO2015036512A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058630B2 (en) 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル, インコーポレイテッド がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン
DK3105226T3 (da) 2014-02-13 2019-10-14 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
EP3359157A4 (en) 2015-10-06 2019-05-15 The Wistar Institute Of Anatomy And Biology METHOD AND COMPOSITIONS FOR THE TREATMENT OF METASTASIVE AND REFRACTORY CANCER DISEASES AND TUMORS
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
US10939164B2 (en) * 2016-05-10 2021-03-02 Rovi Guides, Inc. Method and system for transferring an interactive feature to another device
KR101796684B1 (ko) * 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3058162A1 (en) * 2017-03-30 2018-10-04 Boston Biomedical, Inc. Compositions for treating and/or preventing cancer
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN115487186B (zh) * 2022-09-29 2024-04-16 北京朗瑞邦科技有限公司 一种具有mTOR抑制活性的药物制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
SE0201110D0 (sv) * 2002-04-12 2002-04-12 Astrazeneca Ab New film coating
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
JP2004051506A (ja) * 2002-07-17 2004-02-19 Nichiko Pharmaceutical Co Ltd 経時的な変色を抑制した医薬組成物
JP2004300138A (ja) * 2003-03-18 2004-10-28 Takeda Chem Ind Ltd 安定化された経口固形製剤
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
BRPI0911297A2 (pt) * 2008-04-14 2019-09-24 Ardea Biosciences Inc composição e métodos para preparo e uso das mesmas
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
MX2011009498A (es) * 2009-03-11 2011-10-14 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos.
JP2011162531A (ja) * 2010-02-10 2011-08-25 Takada Seiyaku Kk フェキソフェナジン含有フイルムコーテイング経口製剤
JP5700367B2 (ja) * 2010-05-06 2015-04-15 高田製薬株式会社 パロキセチン含有フイルムコ−テイング経口製剤
WO2012120364A2 (en) * 2011-03-09 2012-09-13 Ideal Cures Pvt. Ltd. Novel immediate release film coating compositions
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib

Similar Documents

Publication Publication Date Title
JP2016531151A5 (enExample)
TWI415635B (zh) 加衣錠片調製物及製備彼之方法
NZ555901A (en) Matrix type sustained-release preparation containing donepezil hydrochloride and / or memantine hydrochloride
US20130216617A1 (en) Pharmaceutical compositions of (r)-lansoprazole
ES2435943T3 (es) Formulaciones de vildagliptina
CA2804749C (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CN108057036B (zh) 一种egfr抑制剂的固体药物组合物
JP7064683B2 (ja) 腸溶層破損防止用組成物
JP2015107977A (ja) 代謝型グルタミン酸5受容体(mGlu5)アンタゴニストの医薬組成物
WO2017103945A1 (en) Pharmaceutical compositions
EP3236952B1 (en) Pharmaceutical tablet composition
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
EP3270911A1 (en) Pharmaceutical compositions of dimethyl fumarate
US20220273619A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolylglycyl-l-tyrosinate and methods for preparing the same
US20200054659A1 (en) Extended release capecitabine capsules
US20160015646A1 (en) Oral delivery system for sorafenib tosylate
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) エルロチニブを有効成分とする医薬錠剤
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib
HK1251880A1 (zh) 一种egfr抑制剂的固体药物组合物
JP6707471B2 (ja) ピロールカルボキサミドの固形組成物
JP2018030810A (ja) ゲフィチニブを有効成分とする医薬錠剤の製造方法
WO2005046652A1 (en) Controlled release ketoprofen formulation
HK40047687B (en) Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof